COMP <GO>
HROW vs MRK // DIVIDEND YIELD & FCF PAYOUT SAFETY
Harrow Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: HROW 4
— MRK 7
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: MRK
LAST: $28.24 (-5.83%) • MKT CAP: $1.12B
dividend-safety
0.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
dividend-safety
2.26%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HROW VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HROW | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.10% | 74.80% | +0.30 | HROW | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 42.90% | 20.70% | +22.20 | HROW | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.6x | 15.3x | +18.30 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.82% | 3.42% | +0.40 | HROW | /fcf-yield <GO> |
| Operating Margin | 11.20% | 34.30% | -23.10 | MRK | /operating-margins <GO> |
| Net Profit Margin | -1.90% | 28.10% | -30.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 36.40% | 1.30% | +35.10 | HROW | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.67 | 5.19 | -2.52 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.5 | 51.7 | -2.20 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.12B | $361.02B | -$359.90B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HROW REV | MRK REV | HROW GROSS % | MRK GROSS % | HROW FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $272.3M | $65.01B | 75.1% | 74.8% | $43.0M | $12.36B |
| FY 2024 | $199.6M | $64.17B | 75.3% | 76.3% | -$23.8M | $18.10B |
| FY 2023 | $130.2M | $60.12B | — | — | $3.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HROW // BETA —
MRK // BETA 0.92